1
|
Al‐Sawaf O, Zhang C, Robrecht S, Tandon M, Panchal A, Fink A, Tausch E, Ritgen M, Kreuzer K, Kim S, Wendtner C, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.49_2880] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- O. Al‐Sawaf
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - C. Zhang
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Robrecht
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - M. Tandon
- Roche Products Limited Welwyn Garden City UK
| | - A. Panchal
- Roche Products Limited Welwyn Garden City UK
| | - A.‐M. Fink
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - E. Tausch
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - M. Ritgen
- University of Schleswig‐Holstein Department II of Internal Medicine Kiel Germany
| | - K.‐A. Kreuzer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | | | - C. Wendtner
- Klinikum Schwabing Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine Munich Germany
| | - B. Eichhorst
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Stilgenbauer
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | | | - M. Hallek
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - K. Fischer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| |
Collapse
|
2
|
Al‐Sawaf O, Robrecht S, Stumpf J, Fink A, Ritgen M, Johansson P, Tausch E, Hoechstetter M, Staber P, Jäger U, Niemann CU, Pallasch C, Kreuzer K, Stilgenbauer S, Fischer K, Wendtner C, Hallek M, Eichhorst B. THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION. Hematol Oncol 2021. [DOI: 10.1002/hon.161_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- O. Al‐Sawaf
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Robrecht
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - J. Stumpf
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - A.‐M. Fink
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - M. Ritgen
- University of Schleswig‐Holstein Department II of Internal Medicine Kiel Germany
| | - P. Johansson
- University Hospital Essen Clinic for Hematology Essen Germany
| | - E. Tausch
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - M. Hoechstetter
- Klinikum Schwabing Department of Hematology Oncology Immunology Palliative Care Infectious Diseases and Tropical Medicine Munich Germany
| | - P. Staber
- Medical University of Vienna Department of Medicine I Division of Hematology & Hemostaseology Vienna Austria
| | - U. Jäger
- Medical University of Vienna Department of Medicine I Division of Hematology & Hemostaseology Vienna Austria
| | - C. U. Niemann
- Department of Haematology Rigshospitalet and Department of Clinical Medicine University of Copenhagen, Denmark Copenhagen Denmark
| | - C. Pallasch
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - K.‐A. Kreuzer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Stilgenbauer
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - K. Fischer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - C. Wendtner
- Klinikum Schwabing Department of Hematology Oncology Immunology Palliative Care Infectious Diseases and Tropical Medicine Munich Germany
| | - M. Hallek
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - B. Eichhorst
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| |
Collapse
|
3
|
Tausch E, Bahlo J, Robrecht S, Schneider C, Bloehdorn J, Schrell S, Galler C, Al-Sawaf O, Fink A, Eichhorst B, Kreuzer K, Tandon M, Humphrey K, Jiang Y, Schary W, Porro Lurà M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. Hematol Oncol 2019. [DOI: 10.1002/hon.53_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- E. Tausch
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - J. Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - S. Robrecht
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - C. Schneider
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - J. Bloehdorn
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - S. Schrell
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - C. Galler
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - O. Al-Sawaf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - A. Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - B. Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - K. Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - M. Tandon
- Clinical Development Oncology; Roche; Welwyn Garden City United Kingdom
| | - K. Humphrey
- Clinical Development Oncology; Roche; Welwyn Garden City United Kingdom
| | - Y. Jiang
- Oncology Biomarker Development; Genentech; South San Francisco United States
| | - W. Schary
- Oncology; Abbvie Inc; North Chicago United States
| | - M. Porro Lurà
- Pharmaceuticals Division; F. Hoffmann - La Roche Ltd; Basel Switzerland
| | - H. Döhner
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - K. Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - M. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - S. Stilgenbauer
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| |
Collapse
|
4
|
Langerbeins P, Bahlo J, Rhein C, Gerwin H, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink A, Kreuzer K, Vehling-Kaiser U, Tausch E, Müller L, Eckart M, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner C, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.7_2629] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Langerbeins
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - J. Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - C. Rhein
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - H. Gerwin
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - P. Cramer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - M. Fürstenau
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - O. Al-Sawaf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - J. von Tresckow
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - A.M. Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - K. Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | | | - E. Tausch
- Internal Medicine III; University Hospital; Ulm Germany
| | - L. Müller
- Hämatologie und Onkologie; Studienzentrum UnterEms; Leer Germany
| | - M. Eckart
- Hämatologie und Onkologie; Onkologische Schwerpunktpraxis; Erlangen Germany
| | - R. Schlag
- Hämatologie und Onkologie; Gemeinschaftspraxis; Würzburg Germany
| | - W. Freier
- Hämatologie und Onkologie; Medicinum; Hildesheim Germany
| | - T. Gaska
- Klinik für Hämatologie und Onkologie; Brüderkrankenhaus St. Josef; Paderborn Germany
| | - C. Balser
- Hämatologie und Onkologie; Internistische Praxis; Marburg Germany
| | - M. Reiser
- PIOH; Praxis Internistischer Onkologie und Hämatologie; Köln Germany
| | - M. Stauch
- Hämatologie; Onkologie, Gerinnung; Ambulantes Zentrum Kronach Germany
| | - C. Wendtner
- Department I of Internal Medicine, Munich Clinic Schwabing; Academic Teaching Hospital of University of Munich; Munich Germany
| | - K. Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - S. Stilgenbauer
- Internal Medicine I; University of Saarland; Homburg Germany
| | - B. Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - M. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| |
Collapse
|
5
|
Fischer K, Porro Lurà M, Al-Sawaf O, Bahlo J, Fink A, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati A, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto L, Utoft Niemann C, Weinkove R, Robinson S, Kipps T, Boettcher S, Tausch E, Schary W, Eichhorst B, Wendtner C, Langerak A, Kreuzer K, Goede V, Stilgenbauer S, Mobasher M, Ritgen M, Hallek M. FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. Hematol Oncol 2019. [DOI: 10.1002/hon.52_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- K. Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Porro Lurà
- Pharmaceuticals Division; PDGo, F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - O. Al-Sawaf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - J. Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - A. Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Tandon
- Clinical Development Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - M. Dixon
- Biostatistics; Roche Products Limited; Welwyn Garden City United Kingdom
| | - S. Robrecht
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - S. Warburton
- Product Development - Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - K. Humphrey
- Clinical Development Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - O. Samoylova
- Hematology Department; Regional Clinical Hospital N.A. Semashko; Nizhny Novgorod Russian Federation
| | - A.M. Liberati
- Division of Onco-Hematology; Santa Maria Terni Hospital, University of Perugia; Perugia Italy
| | - J. Pinilla-Ibarz
- Department of Malignant Hematology; H. Lee Moffitt Cancer Center & Research Institute; Tampa FL United States
| | - S. Opat
- Haematology Department; School of Clinical Sciences at Monash Health; Monash University Victoria Australia
| | - L. Sivcheva
- First Internal Department; MHAT Hristo Botev; AD, Vratsa Bulgaria
| | - K. Le Dû
- Hematology Department; Clinique Victor Hugo; Le Mans France
| | - L.M. Fogliatto
- Department of Hematology; Hospital de Clínicas de Porto Alegre; Porto Alegre Brazil
| | - C. Utoft Niemann
- Department of Hematology; Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark
| | - R. Weinkove
- Wellington Blood & Cancer Centre; Capital & Coast District Health Board, Wellington, New Zealand and Cancer Immunotherapy Programme, Malaghan Institute of Medical Research; Wellington New Zealand
| | - S. Robinson
- Department of Medicine; Division of Hematology, QEII Health Sciences Center; Halifax NS Canada
| | - T.J. Kipps
- Moores Cancer Center; UC San Diego Health; San Diego CA United States
| | - S. Boettcher
- Department III of Internal Medicine; University Hospital Rostock; Rostock Germany
| | - E. Tausch
- Department III of Internal Medicine; Ulm University; Ulm Germany
| | - W.L. Schary
- Clinical Development Oncology; AbbVie Inc.; North Chicago IL United States
| | - B. Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - C. Wendtner
- Department of Hematology; Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine; Klinikum Schwabing Munich Germany
| | - A.W. Langerak
- Department of Immunology; Laboratory Medical Immunology, Erasmus MC; Rotterdam Netherlands
| | - K. Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - V. Goede
- Oncogeriatric Unit; Dept. of Geriatric Medicine, St. Marien Hospital; Cologne Germany
| | - S. Stilgenbauer
- Department III of Internal Medicine, Ulm University, Ulm, Germany and Department for Hematology, Oncology and Rheumatology; Saarland University Medical School; Homburg/Saar Germany
| | - M. Mobasher
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - M. Ritgen
- Department II of Internal Medicine; Campus Kiel, University of Schleswig-Holstein; Kiel Germany
| | - M. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, CECAD (Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases); University of Cologne; Cologne Germany
| |
Collapse
|
6
|
Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink A, Patz M, Tandon M, Humphrey K, Jiang Y, Schary W, Porro Lurà M, Ritgen M, Tausch E, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M, Kreuzer K. HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.68_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- O. Al-Sawaf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - E. Lilienweiss
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - J. Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - S. Robrecht
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - A. Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Patz
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Tandon
- Clinical Development Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - K. Humphrey
- Clinical Development Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - Y. Jiang
- Oncology Biomarker Development; Genentech Inc.; South San Francisco CA United States
| | - W. Schary
- Clinical Development; Oncology, AbbVie Inc.; North Chicago IL United States
| | - M. Porro Lurà
- Pharmaceuticals Division, PDGo; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - M. Ritgen
- Department II of Internal Medicine, Campus Kiel; University of Schleswig-Holstein; Kiel Germany
| | - E. Tausch
- Department III of Internal Medicine; Ulm University; Ulm Germany
| | - S. Stilgenbauer
- Department III of Internal Medicine, Ulm University, Ulm, Germany, and Department for Hematology, Oncology and Rheumatology; Saarland University Medical School; Homburg/Saar Germany
| | - B. Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - K. Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, CECAD (Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases); University of Cologne; Cologne Germany
| | - K. Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| |
Collapse
|
7
|
Heyne E, Schwarzer M, Schenkl C, Kreuzer K, Schrepper A, Doenst T. Detrimental Effects of Metformin on Mitochondrial Function in Healthy Rats. Thorac Cardiovasc Surg 2019. [DOI: 10.1055/s-0039-1678920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- E. Heyne
- Jena University Hospital, Cardiothoracic Surgery, Jena, Germany
| | - M. Schwarzer
- Jena University Hospital, Cardiothoracic Surgery, Jena, Germany
| | - C. Schenkl
- Jena University Hospital, Cardiothoracic Surgery, Jena, Germany
| | - K. Kreuzer
- Jena University Hospital, Cardiothoracic Surgery, Jena, Germany
| | - A. Schrepper
- Jena University Hospital, Cardiothoracic Surgery, Jena, Germany
| | - T. Doenst
- Jena University Hospital, Cardiothoracic Surgery, Jena, Germany
| |
Collapse
|
8
|
Borchmann P, Eichhorst B, Hellmann M, Hübel K, Kochanek M, Kreuzer K, Reiser M, Hallek M. Hämatologie 2008. Dtsch Med Wochenschr 2008. [DOI: 10.1055/s-0028-1082776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Affiliation(s)
- P Borchmann
- Klinik I für Innere Medizin, Universitätsklinikum, Joseph-Stelzmann Str. 9, 50924 Köln.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
|
11
|
Abstract
The majority of DNA lesions resulting from interactions of carcinogens with DNA are usually either single strand breaks or lesions which are converted to single strand breaks by treatment of DNA with alkaline solutions. A sensitive method of detecting DNA single strand breaks is the alkaline filter elution of DNA. We started to test this method for biomonitoring occupational exposure with sensitive experimental conditions using pH 12.6, where most alkali-labile DNA lesions are converted to single strand breaks. Under our conditions statistically significant differences can be detected between the elution rates of untreated V79 cells and cells treated with [3H]-thymidine 24 h prior to the elution. Statistically significant increases were detected in the elution rates of male smoking automobile mechanics and male smoking painters compared to non-smoking controls. No statistically significant differences were detected in the elution rates of male non-smoking automobile mechanics and male workers with a suspected exposure to halogenated aromatics compared to male controls. No statistically significant differences were observed in the elution rates of female smoking dry-cleaning workers compared to female smoking controls. Our experience showed that the alkaline elution technique can be a valuable tool for monitoring DNA damage in peripheral lymphocytes in man.
Collapse
Affiliation(s)
- G Doerjer
- Institut für Toxikologie, Mainz, Federal Republic of Germany
| | | | | | | |
Collapse
|
12
|
Abstract
A fine structure map of the phoR region of E. coli, mutations of which affect the rate of alkaline phosphatase synthesis, was constructed by Hfr X F- crosses. Mutations causing three different phenotypes (previously reported as phoRa, phoRb, phoRc (Garen and Echols 1962a,b) are clustered in three closely linked genetic loci. PhoR mutants of all three types, including the phoRb type not previously tested, are recessive to wild-type phoR+. In addition, phoRa and phoRc complement each other, while phoRa and phoRb do not. Our results support the hypothesis of Morris et al. (1974) that phoRc mutants represent a cistron (phoB) different from phoR.
Collapse
|
13
|
Bruch H, Kreuzer K, Meyerhöfer H. [Therapeutic results in cervix carcinoma at a large municipal hospital]. Zentralbl Gynakol 1969; 91:1321-7. [PMID: 4983836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
14
|
Kreuzer K, Welsch H, Sessner HH, Schürger R. [Diagnosis and therapy of generalized Shwartzman-Sanarelli phenomenon]. Zentralbl Gynakol 1969; 91:504-9. [PMID: 5373285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|